Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDAPRNewsWire • 11/18/21
Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/03/21
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate UpdatesPRNewsWire • 11/03/21
Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021PRNewsWire • 10/28/21
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?The Motley Fool • 10/11/21
Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C MeetingPRNewsWire • 10/04/21
Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare ConferencePRNewsWire • 09/21/21
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/09/21
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate UpdatesPRNewsWire • 08/09/21
Will Heron Therapeutics (HRTX) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/28/21
Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free RecoveryPRNewsWire • 07/28/21
Heron Therapeutics' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged PatientsBenzinga • 07/22/21
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™PRNewsWire • 07/21/21
Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™PRNewsWire • 07/06/21
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 HoursPRNewsWire • 07/01/21
Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid CrisisThe Motley Fool • 06/02/21
Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is ImportantBenzinga • 05/13/21